Significance of Geriatric Assessment for Optimal Treatment of Older Cancer Patients
试验速览
- 阶段
- 不适用
- 入组人数
- 114
- 试验地点
- 2
- 主要终点
- Feasibility of planned oncologic treatment (number of participants, who complete the planned oncologic treatment)
研究概览
简要总结
In a randomized controlled trial, the investigators wish to investigate, if oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in older frail patients with gynaecologic and urologic cancer is superior to standard assessment (PS and clinical assessment) in oncologic treatment decision.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically verified gynaecologic cancer (ovarian, uterine, or cervical cancer) or urologic cancer (prostate, bladder, or kidney cancer).
- •Suited for first line medical oncologic treatment with chemotherapy and/or targeted therapy.
- •Age ≥ 70 years.
- •Understands, speaks, and writes Danish.
- •Signed informed consent.
排除标准
- •Previous cancer diagnosis except for carcinoma in situ of the cervix or skin cancer other than malignant melanoma.
- •Previous chemotherapy and/or targeted therapy for current cancer diagnosis.
- •Previous radiation therapy or concomitant radiotherapy for current cancer diagnosis.
- •Surgery within the last 4 weeks.
研究组 & 干预措施
A (experimental group)
Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
干预措施: G8 screening (Other)
A (experimental group)
Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
干预措施: Geriatric assessment (Other)
B (control group)
Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
结局指标
主要结局
Feasibility of planned oncologic treatment (number of participants, who complete the planned oncologic treatment)
时间窗: 2 years
次要结局
未报告次要终点
研究者
Sambavy Nadaraja
MD, PhD student
Odense University Hospital